Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762875 · ClinicalTrials.gov registry record · Phase 2
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
A Phase 2 study, sponsored by Ensoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04762875 is a Phase 2 study that was terminated before completion, run by Ensoma. The registered enrollment target is 7 participants.
The verdict
NCT04762875, a Phase 2 study, was terminated before completion, sponsored by Ensoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.
Interventions
- BIOLOGICAL MGTA-145
- BIOLOGICAL Plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2022-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04762875
The ClinicalTrials.gov registry entry for NCT04762875 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ensoma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MGTA-145 is the first listed.
NCT04762875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04762875 about?
NCT04762875 is a clinical study titled "MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies". This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.
What is the current status of trial NCT04762875?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-06-16. Estimated completion is 2022-03-14.
What interventions are being tested in trial NCT04762875?
The interventions under investigation include: MGTA-145 (BIOLOGICAL), Plerixafor (BIOLOGICAL).
Who is sponsoring clinical trial NCT04762875?
This trial is sponsored by Ensoma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.